News articles about Tabula Rasa HealthCare (NASDAQ:TRHC) have trended somewhat positive on Tuesday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tabula Rasa HealthCare earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.7937313956612 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Tabula Rasa HealthCare Subsidiary CareKinesis is Exclusive Provider of In-Home Medication Reminder Device for PACE Organizations (finance.yahoo.com)
- Beta as a Common Measure of Risk – Tabula Rasa HealthCare, (NASDAQ: TRHC) (stocksnewstimes.com)
- Tabula Rasa HealthCare Inc (TRHC) Short Interest Update (americanbankingnews.com)
- Tabula Rasa HealthCare (TRHC) Price Target Raised to $18.00 at Robert W. Baird (americanbankingnews.com)
- Tabula Rasa HealthCare Inc (TRHC) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
Shares of NASDAQ:TRHC opened at $40.57 on Tuesday. The firm has a market cap of $799.34, a price-to-earnings ratio of -1,014.25, a P/E/G ratio of 8.88 and a beta of 2.34. Tabula Rasa HealthCare has a 12-month low of $11.59 and a 12-month high of $41.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.21 and a quick ratio of 1.11.
TRHC has been the topic of several research reports. Oppenheimer initiated coverage on Tabula Rasa HealthCare in a research report on Monday, December 18th. They set an “outperform” rating and a $35.00 price target on the stock. BidaskClub upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Zacks Investment Research lowered Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Citigroup initiated coverage on Tabula Rasa HealthCare in a research report on Thursday, January 4th. They set a “buy” rating on the stock. Finally, Piper Jaffray lifted their price target on Tabula Rasa HealthCare to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. Tabula Rasa HealthCare presently has an average rating of “Buy” and a consensus price target of $36.40.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $34.75, for a total transaction of $278,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce Luehrs sold 12,234 shares of Tabula Rasa HealthCare stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $38.01, for a total value of $465,014.34. The disclosure for this sale can be found here. Insiders have sold 324,000 shares of company stock valued at $11,309,958 in the last quarter. 45.80% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-tabula-rasa-healthcare-trhc-share-price.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.